Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012

Trial Profile

Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Acronyms GO-EASY
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 12 May 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
    • 14 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 15 Aug 2012 Merck added as trial sponsor and lead trial centre as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top